Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
First Tracks Biotherapeutics (TRAX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
● GlobeNewsWireNov 3, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…
● GlobeNewsWireNov 3, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…
● GlobeNewsWireOct 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces $200 Million Private Placement
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements. TRAX's ANB033 demonstrat…
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
First Tracks Biotherapeutics (NASDAQ: TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-relate…
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $44.…
● GlobeNewsWireAug 26, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…
Kept in their own lane. A press release is the company talking, not reporting.
Tied to events
No upcoming events in the feeds.
Most covered today
Quiet tape today.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.